登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
ClinicalTrials.gov 上登记的一项胶质瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06763965,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Patients with high-grade glioma who have recurred/progressed after receiving standard therapy as confirmed by histopathological confirmation meeting the 2021 World Health Organization (WHO) classification criteria for central nervous system tumors;
入选标准第 2 条
Females of childbearing potential, must have a negative blood pregnancy test result within 7 days prior to the first dose and be willing to undergo additional pregnancy tests during the study. Females of childbearing potential who have not undergone surgical sterilization (i.e., bilateral tubal ligation, bilateral oophorectomy, or total hysterectomy) or are not postmenopausal; Menopause is the absence of menopause for 12 months in women over ≥ age of 45 and the exclusion of other causes of amenorrhea. In addition, serum follicle-stimulating hormone (FSH) levels in women under 50 years of age must be in the postmenopausal range for menopause to be confirmed;
入选标准第 9 条
Received anti-tumor drug therapy such as radiotherapy, chemotherapy, biological therapy, endocrine therapy, targeted therapy and other anti-tumor drugs within 4 weeks before the first dose (excluding immunotherapy, nitrosourea, mitomycin C, oral fluorouracil, small molecule targeted drugs, and traditional Chinese medicines with anti-tumor indications);
排除标准第 1 条
Subjects who have received systemic corticosteroids (>10 mg/day of prednisone or equivalent) or other immunosuppressants within 14 days prior to the first dose; except in the following cases: use of topical, ocular, intra-articular, intranasal, and inhaled corticosteroid treatments; short-term use of corticosteroids for prophylactic treatment (e.g., prevention of contrast agent allergy);
排除标准第 9 条
Previous immunotherapy with immune-related adverse events (irAE) of grade ≥3;
排除标准第 18 条
Karnofsky Performance Score (KPS) ≥ 60 points (see Appendix 2);
入选标准第 3 条
History of immunodeficiency, including positive HIV antibody test;
排除标准第 11 条
Active hepatitis B (HBsAg positive and HBV-DNA > 500 IU/ml or lower limit of detection at the study center [only if the study center's detection limit is higher than 500 IU/ml]); active hepatitis C (HCV antibody positive and HCV-RNA > the detection limit at the study center), positive treponema pallidum antibody for syphilis;
排除标准第 12 条
Subjects of childbearing potential and sexually active partners must be willing to use a medically approved and effective method of contraception, such as a double-barrier method of contraception, during treatment and for 6 months after the last dose, and the male agrees not to donate sperm;
入选标准第 8 条
Pregnant or breastfeeding women;
排除标准第 26 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06763965,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Aged 18 years or older, both male and female are eligible; Patients with high-grade glioma who have recurred/progressed after receiving standard therapy as confirmed by histopathological confirmation meeting the 2021 World Health Organization (WHO) classification criteria for central nervous system tumors; Karnofsky Performance Score (KPS) ≥ 60 points (see Appendix 2); Suitable for placement of Ommaya sac as judged by the investigator to be eligible for administration; Estimated survival ≥ 3 months; Good organ function; Voluntary participation and ability to sign informed consent form prior to the start of study-related procedures, after explaining the content of the study; Subjects of childbearing potential and sexually active partners must be willing to use a medically approved and effective method of contraception, such as a double-barrier method of contraception, during treatment and for 6 months after the last dose, and the male agrees not to donate sperm; Females of childbearing potential, must have a negative blood pregnancy test result within 7 days prior to the first dose and be willing to undergo additional pregnancy tests during the study. Females of childbearing potential who have not undergone surgical sterilization (i.e., bilateral tubal ligation, bilateral oophorectomy, or total hysterectomy) or are not postmenopausal; Menopause is the absence of menopause for 12 months in women over ≥ age of 45 and the exclusion of other causes of amenorrhea. In addition, serum follicle-stimulating hormone (FSH) levels in women under 50 years of age must be in the postmenopausal range for menopause to be confirmed; Good compliance, willing and able to follow all research procedures, and cooperate with observation and follow-up.排除标准:Exclusion Criteria:
Received anti-tumor drug therapy such as radiotherapy, chemotherapy, biological therapy, endocrine therapy, targeted therapy and other anti-tumor drugs within 4 weeks before the first dose (excluding immunotherapy, nitrosourea, mitomycin C, oral fluorouracil, small molecule targeted drugs, and traditional Chinese medicines with anti-tumor indications); Treatment with any other unmarketed investigational drug within 4 weeks prior to the first dose; Surgical surgery of major organs within 4 weeks prior to the first dose (excluding live puncture) or have had significant trauma, or need to undergo elective surgery during the study; Those who have a history of cell therapy, gene therapy, and oncolytic virus therapy in the past; Those who have known or suspected hypersensitivity to the active ingredients of the study drug, excipients, and imaging contrast agents; Those who have a history of organ transplantation or plan to undergo organ transplantation during the study; Patients with active infection or uncontrollable infection requiring intravenous systemic therapy, or fever of unknown cause > 38.5°C during the screening period and before the first dose; Accompanied by severe coagulation disorder or other evidence of obvious bleeding risk; history of gastrointestinal bleeding; Any other ≥ CTCAE grade 2 bleeding event within the past 6 months; Subjects who have received systemic corticosteroids (>10 mg/day of prednisone or equivalent) or other immunosuppressants within 14 days prior to the first dose; except in the following cases: use of topical, ocular, intra-articular, intranasal, and inhaled corticosteroid treatments; short-term use of corticosteroids for prophylactic treatment (e.g., prevention of contrast agent allergy); Adverse reactions from previous anti-tumor treatments have not yet recovered to ≤ Grade 1 according to CTCAE 5.0 (except for toxicities deemed to pose no safety risk by the investigator, such as hair loss, Grade 2 peripheral neuropathy, etc.); History of immunodeficiency, including positive HIV antibody test; Active hepatitis B (HBsAg positive and HBV-DNA > 500 IU/ml or lower limit of detection at the study center [only if the study center's detection limit is higher than 500 IU/ml]); active hepatitis C (HCV antibody positive and HCV-RNA > the detection limit at the study center), positive treponema pallidum antibody for syphilis; Hypertension poorly controlled as judged by the investigator (arterial hypertension not controlled despite standard treatment: systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg); History of severe cardiovascular disease, such as: ventricular arrhythmia requiring clinical intervention; QTc interval >480 ms; acute coronary syndrome, congestive heart failure, stroke, or other grade III or higher cardiovascular events within 6 months prior to first administration; New York Heart Association (NYHA) functional class ≥II (see Appendix 4) or left ventricular ejection fraction (LVEF) <50%; Presence of other untreated malignancies within the past 3 years or currently, except for carcinoma in situ that is considered clinically curable, such as in situ cervical cancer and basal cell carcinoma; Active or past autoimmune diseases with potential for recurrence (including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), except clinically stable autoimmune thyroiditis; Received live attenuated or recombinant vaccines within 4 weeks before first administration, or received inactivated vaccines within 2 weeks before first administration; Previous immunotherapy with immune-related adverse events (irAE) of grade ≥3; Tumorous lesions in the brainstem, cerebellum, posterior cranial fossa, or spinal cord, or presence of leptomeningeal disease; Diffuse subependymal and subarachnoid space disease; Patients whose lesions are closely related to the ventricles, posing a risk of intraventricular dissemination (patients judged by the investigator that the oncolytic virus cannot directly reach the ventricles after administration may be included); History of encephalitis, multiple sclerosis, or other central nervous system infections; Patients with brain herniation syndrome; Known alcohol or drug dependence; Patients with psychiatric disorders or poor compliance; Pregnant or breastfeeding women; Participants who, in the opinion of the investigator, have other serious systemic diseases or other reasons that make them unsuitable for participation in this clinical study.
引自 ClinicalTrials.gov, NCT06763965, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06763965,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。